nodes	percent_of_prediction	percent_of_DWPC	metapath
Danazol—CYP3A4—bone cancer	0.746	1	CbGaD
Danazol—Guillain-Barre syndrome—Methotrexate—bone cancer	0.00466	0.0535	CcSEcCtD
Danazol—Arterial thrombosis—Methotrexate—bone cancer	0.00251	0.0288	CcSEcCtD
Danazol—Ethinyl Estradiol—NR1I2—bone cancer	0.00235	0.331	CrCbGaD
Danazol—Nodule—Methotrexate—bone cancer	0.0023	0.0264	CcSEcCtD
Danazol—Pigmentation disorder—Epirubicin—bone cancer	0.0019	0.0218	CcSEcCtD
Danazol—Pigmentation disorder—Doxorubicin—bone cancer	0.00175	0.0201	CcSEcCtD
Danazol—Laboratory test abnormal—Epirubicin—bone cancer	0.00151	0.0174	CcSEcCtD
Danazol—Laboratory test abnormal—Doxorubicin—bone cancer	0.0014	0.0161	CcSEcCtD
Danazol—Interstitial pneumonia—Methotrexate—bone cancer	0.0014	0.0161	CcSEcCtD
Danazol—Body temperature increased—Carboplatin—bone cancer	0.00118	0.0136	CcSEcCtD
Danazol—Fluid retention—Cisplatin—bone cancer	0.00117	0.0134	CcSEcCtD
Danazol—Gingival bleeding—Epirubicin—bone cancer	0.00111	0.0128	CcSEcCtD
Danazol—Pelvic pain—Epirubicin—bone cancer	0.00104	0.0119	CcSEcCtD
Danazol—Gingival bleeding—Doxorubicin—bone cancer	0.00103	0.0118	CcSEcCtD
Danazol—Nasal congestion—Cisplatin—bone cancer	0.000982	0.0113	CcSEcCtD
Danazol—Pelvic pain—Doxorubicin—bone cancer	0.000962	0.0111	CcSEcCtD
Danazol—Interstitial lung disease—Methotrexate—bone cancer	0.000955	0.011	CcSEcCtD
Danazol—Seborrhoeic dermatitis—Epirubicin—bone cancer	0.000928	0.0107	CcSEcCtD
Danazol—Thrombosis—Epirubicin—bone cancer	0.000894	0.0103	CcSEcCtD
Danazol—Seborrhoeic dermatitis—Doxorubicin—bone cancer	0.000859	0.00986	CcSEcCtD
Danazol—Irritability—Cisplatin—bone cancer	0.000853	0.0098	CcSEcCtD
Danazol—Thrombosis—Doxorubicin—bone cancer	0.000827	0.0095	CcSEcCtD
Danazol—Cramp muscle—Cisplatin—bone cancer	0.000805	0.00925	CcSEcCtD
Danazol—Cortisone acetate—CYP3A4—bone cancer	0.000805	0.113	CrCbGaD
Danazol—Etonogestrel—CYP3A4—bone cancer	0.000781	0.11	CrCbGaD
Danazol—Dysphonia—Epirubicin—bone cancer	0.000769	0.00883	CcSEcCtD
Danazol—Pancreatitis—Cisplatin—bone cancer	0.000758	0.0087	CcSEcCtD
Danazol—Amenorrhoea—Epirubicin—bone cancer	0.00072	0.00827	CcSEcCtD
Danazol—Jaundice cholestatic—Epirubicin—bone cancer	0.00072	0.00827	CcSEcCtD
Danazol—Dysphonia—Doxorubicin—bone cancer	0.000711	0.00817	CcSEcCtD
Danazol—Acute coronary syndrome—Cisplatin—bone cancer	0.000679	0.0078	CcSEcCtD
Danazol—Myocardial infarction—Cisplatin—bone cancer	0.000675	0.00776	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—RB1—bone cancer	0.000668	0.00418	CbGpPWpGaD
Danazol—Jaundice cholestatic—Doxorubicin—bone cancer	0.000666	0.00765	CcSEcCtD
Danazol—Amenorrhoea—Doxorubicin—bone cancer	0.000666	0.00765	CcSEcCtD
Danazol—CYP19A1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000652	0.00409	CbGpPWpGaD
Danazol—CCL2—Metabolism of proteins—TUBB4B—bone cancer	0.000639	0.004	CbGpPWpGaD
Danazol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000633	0.00397	CbGpPWpGaD
Danazol—ESR1—Estrogen signaling pathway—JUN—bone cancer	0.00062	0.00388	CbGpPWpGaD
Danazol—AR—Notch-mediated HES/HEY network—RB1—bone cancer	0.000613	0.00384	CbGpPWpGaD
Danazol—CCL2—TNF alpha Signaling Pathway—JUN—bone cancer	0.000604	0.00378	CbGpPWpGaD
Danazol—Fluid retention—Epirubicin—bone cancer	0.000601	0.0069	CcSEcCtD
Danazol—Visual impairment—Cisplatin—bone cancer	0.000596	0.00685	CcSEcCtD
Danazol—ESR1—FOXM1 transcription factor network—CDK4—bone cancer	0.000594	0.00372	CbGpPWpGaD
Danazol—PGR—Gene Expression—ZNF77—bone cancer	0.000588	0.00368	CbGpPWpGaD
Danazol—Flushing—Cisplatin—bone cancer	0.000574	0.00659	CcSEcCtD
Danazol—Photosensitivity—Methotrexate—bone cancer	0.000559	0.00642	CcSEcCtD
Danazol—Fluid retention—Doxorubicin—bone cancer	0.000556	0.00638	CcSEcCtD
Danazol—Levonorgestrel—CYP3A4—bone cancer	0.000553	0.0777	CrCbGaD
Danazol—CCL2—Metabolism of proteins—TUBB2A—bone cancer	0.000551	0.00345	CbGpPWpGaD
Danazol—CCL2—Spinal Cord Injury—PTGS2—bone cancer	0.000549	0.00344	CbGpPWpGaD
Danazol—Alopecia—Cisplatin—bone cancer	0.000547	0.00628	CcSEcCtD
Danazol—CCL2—Oncostatin M Signaling Pathway—TP53—bone cancer	0.000527	0.0033	CbGpPWpGaD
Danazol—Hepatic function abnormal—Epirubicin—bone cancer	0.000525	0.00603	CcSEcCtD
Danazol—AR—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000525	0.00329	CbGpPWpGaD
Danazol—Photosensitivity—Epirubicin—bone cancer	0.000523	0.00601	CcSEcCtD
Danazol—CCL2—GPCR ligand binding—SMO—bone cancer	0.000521	0.00326	CbGpPWpGaD
Danazol—CCL2—Folate Metabolism—TP53—bone cancer	0.00052	0.00326	CbGpPWpGaD
Danazol—Visual disturbance—Methotrexate—bone cancer	0.000518	0.00595	CcSEcCtD
Danazol—Muscle spasms—Cisplatin—bone cancer	0.000518	0.00595	CcSEcCtD
Danazol—ESR1—FOXM1 transcription factor network—RB1—bone cancer	0.000517	0.00324	CbGpPWpGaD
Danazol—Vision blurred—Cisplatin—bone cancer	0.000507	0.00583	CcSEcCtD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—MMP2—bone cancer	0.000505	0.00316	CbGpPWpGaD
Danazol—Tremor—Cisplatin—bone cancer	0.000505	0.00579	CcSEcCtD
Danazol—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000504	0.00316	CbGpPWpGaD
Danazol—CCL2—AP-1 transcription factor network—TP53—bone cancer	0.000496	0.00311	CbGpPWpGaD
Danazol—ESR1—FOXM1 transcription factor network—MMP2—bone cancer	0.000496	0.0031	CbGpPWpGaD
Danazol—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—bone cancer	0.000491	0.00308	CbGpPWpGaD
Danazol—Hepatic function abnormal—Doxorubicin—bone cancer	0.000486	0.00558	CcSEcCtD
Danazol—Photosensitivity—Doxorubicin—bone cancer	0.000484	0.00556	CcSEcCtD
Danazol—Leukopenia—Cisplatin—bone cancer	0.000482	0.00554	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—MMP9—bone cancer	0.000482	0.00302	CbGpPWpGaD
Danazol—ESR1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.00048	0.00301	CbGpPWpGaD
Danazol—ESR1—ATF-2 transcription factor network—PLAU—bone cancer	0.000479	0.003	CbGpPWpGaD
Danazol—AR—FOXA1 transcription factor network—JUN—bone cancer	0.000479	0.003	CbGpPWpGaD
Danazol—GNRHR—GPCR ligand binding—SMO—bone cancer	0.000477	0.00299	CbGpPWpGaD
Danazol—AR—Regulation of Androgen receptor activity—MDM2—bone cancer	0.000475	0.00297	CbGpPWpGaD
Danazol—Irritability—Methotrexate—bone cancer	0.000468	0.00538	CcSEcCtD
Danazol—Convulsion—Cisplatin—bone cancer	0.000467	0.00536	CcSEcCtD
Danazol—PGR—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000466	0.00292	CbGpPWpGaD
Danazol—Ethinyl Estradiol—CYP3A4—bone cancer	0.000466	0.0655	CrCbGaD
Danazol—Mood swings—Methotrexate—bone cancer	0.000465	0.00534	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000458	0.00287	CbGpPWpGaD
Danazol—CYP19A1—Tryptophan metabolism—MDM2—bone cancer	0.000458	0.00286	CbGpPWpGaD
Danazol—Anxiety—Cisplatin—bone cancer	0.000457	0.00525	CcSEcCtD
Danazol—AR—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000456	0.00286	CbGpPWpGaD
Danazol—Prednisone—CYP3A4—bone cancer	0.000454	0.0639	CrCbGaD
Danazol—ESR1—ATF-2 transcription factor network—CDK4—bone cancer	0.000453	0.00283	CbGpPWpGaD
Danazol—Affect lability—Epirubicin—bone cancer	0.000452	0.00519	CcSEcCtD
Danazol—Migraine—Epirubicin—bone cancer	0.000452	0.00519	CcSEcCtD
Danazol—AR—Gene Expression—ZNF77—bone cancer	0.000448	0.0028	CbGpPWpGaD
Danazol—Norethindrone—CYP3A4—bone cancer	0.000448	0.063	CrCbGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000447	0.0028	CbGpPWpGaD
Danazol—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000443	0.00277	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—GRM4—bone cancer	0.000441	0.00276	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—RGS1—bone cancer	0.000441	0.00276	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000441	0.00276	CbGpPWpGaD
Danazol—Oedema—Cisplatin—bone cancer	0.000439	0.00505	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—RGS1—bone cancer	0.000438	0.00274	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—GRM4—bone cancer	0.000438	0.00274	CbGpPWpGaD
Danazol—Mood swings—Epirubicin—bone cancer	0.000435	0.005	CcSEcCtD
Danazol—Thrombocytopenia—Cisplatin—bone cancer	0.00043	0.00494	CcSEcCtD
Danazol—Tachycardia—Cisplatin—bone cancer	0.000429	0.00493	CcSEcCtD
Danazol—Methyltestosterone—CYP3A4—bone cancer	0.000425	0.0598	CrCbGaD
Danazol—Hyperhidrosis—Cisplatin—bone cancer	0.000425	0.00488	CcSEcCtD
Danazol—Eosinophilia—Methotrexate—bone cancer	0.00042	0.00482	CcSEcCtD
Danazol—Abdominal pain upper—Epirubicin—bone cancer	0.000419	0.00482	CcSEcCtD
Danazol—Affect lability—Doxorubicin—bone cancer	0.000418	0.0048	CcSEcCtD
Danazol—Migraine—Doxorubicin—bone cancer	0.000418	0.0048	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—PLAU—bone cancer	0.000418	0.00262	CbGpPWpGaD
Danazol—Pancreatitis—Methotrexate—bone cancer	0.000416	0.00478	CcSEcCtD
Danazol—PGR—Generic Transcription Pathway—NR1I2—bone cancer	0.000413	0.00259	CbGpPWpGaD
Danazol—AR—Regulation of Androgen receptor activity—JUN—bone cancer	0.000413	0.00258	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000407	0.00255	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000405	0.00253	CbGpPWpGaD
Danazol—Mood swings—Doxorubicin—bone cancer	0.000403	0.00462	CcSEcCtD
Danazol—GNRHR—Signaling by GPCR—RGS1—bone cancer	0.000401	0.00251	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—GRM4—bone cancer	0.000401	0.00251	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Cisplatin—bone cancer	0.0004	0.0046	CcSEcCtD
Danazol—ESR1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000395	0.00247	CbGpPWpGaD
Danazol—Paraesthesia—Cisplatin—bone cancer	0.000395	0.00453	CcSEcCtD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000394	0.00247	CbGpPWpGaD
Danazol—ESR1—ATF-2 transcription factor network—RB1—bone cancer	0.000394	0.00246	CbGpPWpGaD
Danazol—Eosinophilia—Epirubicin—bone cancer	0.000393	0.00451	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—EGFR—bone cancer	0.000389	0.00244	CbGpPWpGaD
Danazol—Pancreatitis—Epirubicin—bone cancer	0.000389	0.00447	CcSEcCtD
Danazol—Abdominal pain upper—Doxorubicin—bone cancer	0.000388	0.00446	CcSEcCtD
Danazol—Photosensitivity reaction—Methotrexate—bone cancer	0.000387	0.00445	CcSEcCtD
Danazol—CCL2—Metabolism of proteins—EIF2S1—bone cancer	0.000384	0.00241	CbGpPWpGaD
Danazol—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—bone cancer	0.000384	0.00241	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—GRM1—bone cancer	0.000383	0.0024	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000382	0.00239	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—GRM1—bone cancer	0.00038	0.00238	CbGpPWpGaD
Danazol—ESR1—Plasma membrane estrogen receptor signaling—MMP9—bone cancer	0.00038	0.00238	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000379	0.00238	CbGpPWpGaD
Danazol—ESR1—ATF-2 transcription factor network—MMP2—bone cancer	0.000378	0.00236	CbGpPWpGaD
Danazol—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000375	0.00431	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000374	0.00234	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.00037	0.00232	CbGpPWpGaD
Danazol—ESR1—FOXA1 transcription factor network—JUN—bone cancer	0.000369	0.00231	CbGpPWpGaD
Danazol—AR—Androgen receptor signaling pathway—RB1—bone cancer	0.000368	0.0023	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000365	0.00229	CbGpPWpGaD
Danazol—Eosinophilia—Doxorubicin—bone cancer	0.000364	0.00418	CcSEcCtD
Danazol—Sweating—Methotrexate—bone cancer	0.000363	0.00416	CcSEcCtD
Danazol—Photosensitivity reaction—Epirubicin—bone cancer	0.000362	0.00416	CcSEcCtD
Danazol—Weight increased—Epirubicin—bone cancer	0.000361	0.00415	CcSEcCtD
Danazol—Haematuria—Methotrexate—bone cancer	0.000361	0.00414	CcSEcCtD
Danazol—Pancreatitis—Doxorubicin—bone cancer	0.00036	0.00414	CcSEcCtD
Danazol—ESR1—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000353	0.00221	CbGpPWpGaD
Danazol—ESR1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000351	0.0022	CbGpPWpGaD
Danazol—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000351	0.00403	CcSEcCtD
Danazol—Body temperature increased—Cisplatin—bone cancer	0.000347	0.00399	CcSEcCtD
Danazol—GNRHR—Signaling by GPCR—GRM1—bone cancer	0.000347	0.00217	CbGpPWpGaD
Danazol—CYP19A1—Biological oxidations—CYP3A4—bone cancer	0.000347	0.00217	CbGpPWpGaD
Danazol—ESR1—Gene Expression—ZNF77—bone cancer	0.000345	0.00216	CbGpPWpGaD
Danazol—Jaundice—Epirubicin—bone cancer	0.000345	0.00396	CcSEcCtD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000344	0.00215	CbGpPWpGaD
Danazol—CYP19A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000342	0.00214	CbGpPWpGaD
Danazol—Haemoglobin—Methotrexate—bone cancer	0.000341	0.00392	CcSEcCtD
Danazol—PGR—Signaling by ERBB4—KIT—bone cancer	0.000341	0.00213	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.00034	0.00213	CbGpPWpGaD
Danazol—Haemorrhage—Methotrexate—bone cancer	0.000339	0.0039	CcSEcCtD
Danazol—Sweating—Epirubicin—bone cancer	0.000339	0.0039	CcSEcCtD
Danazol—Haematuria—Epirubicin—bone cancer	0.000337	0.00388	CcSEcCtD
Danazol—Photosensitivity reaction—Doxorubicin—bone cancer	0.000335	0.00385	CcSEcCtD
Danazol—Weight increased—Doxorubicin—bone cancer	0.000334	0.00384	CcSEcCtD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000329	0.00206	CbGpPWpGaD
Danazol—Visual impairment—Methotrexate—bone cancer	0.000327	0.00376	CcSEcCtD
Danazol—CCL2—Spinal Cord Injury—TP53—bone cancer	0.000327	0.00205	CbGpPWpGaD
Danazol—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000325	0.00373	CcSEcCtD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000322	0.00201	CbGpPWpGaD
Danazol—Erythema multiforme—Methotrexate—bone cancer	0.000321	0.00369	CcSEcCtD
Danazol—Hydrocortisone—CYP3A4—bone cancer	0.00032	0.045	CrCbGaD
Danazol—Haemoglobin—Epirubicin—bone cancer	0.000319	0.00367	CcSEcCtD
Danazol—Jaundice—Doxorubicin—bone cancer	0.000319	0.00367	CcSEcCtD
Danazol—Haemorrhage—Epirubicin—bone cancer	0.000318	0.00365	CcSEcCtD
Danazol—Asthenia—Cisplatin—bone cancer	0.000315	0.00362	CcSEcCtD
Danazol—AR—Generic Transcription Pathway—NR1I2—bone cancer	0.000315	0.00197	CbGpPWpGaD
Danazol—Sweating—Doxorubicin—bone cancer	0.000314	0.00361	CcSEcCtD
Danazol—AR—Androgen receptor signaling pathway—MDM2—bone cancer	0.000314	0.00196	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000313	0.00196	CbGpPWpGaD
Danazol—Haematuria—Doxorubicin—bone cancer	0.000312	0.00359	CcSEcCtD
Danazol—AR—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.00031	0.00194	CbGpPWpGaD
Danazol—Visual impairment—Epirubicin—bone cancer	0.000306	0.00352	CcSEcCtD
Danazol—Chills—Methotrexate—bone cancer	0.000305	0.0035	CcSEcCtD
Danazol—Erythema multiforme—Epirubicin—bone cancer	0.0003	0.00345	CcSEcCtD
Danazol—Alopecia—Methotrexate—bone cancer	0.0003	0.00345	CcSEcCtD
Danazol—AR—Regulation of nuclear beta catenin signaling and target gene transcription—JUN—bone cancer	0.000297	0.00186	CbGpPWpGaD
Danazol—CYP19A1—Biological oxidations—GSTP1—bone cancer	0.000296	0.00186	CbGpPWpGaD
Danazol—Haemoglobin—Doxorubicin—bone cancer	0.000295	0.00339	CcSEcCtD
Danazol—Flushing—Epirubicin—bone cancer	0.000295	0.00339	CcSEcCtD
Danazol—ESR1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000295	0.00184	CbGpPWpGaD
Danazol—Haemorrhage—Doxorubicin—bone cancer	0.000294	0.00338	CcSEcCtD
Danazol—AR—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.000294	0.00184	CbGpPWpGaD
Danazol—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000292	0.00183	CbGpPWpGaD
Danazol—CYP19A1—Metapathway biotransformation—GSTP1—bone cancer	0.000292	0.00183	CbGpPWpGaD
Danazol—ESR1—ATF-2 transcription factor network—JUN—bone cancer	0.000292	0.00183	CbGpPWpGaD
Danazol—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP9—bone cancer	0.000289	0.00181	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000288	0.0018	CbGpPWpGaD
Danazol—PGR—Gene Expression—FUS—bone cancer	0.000287	0.0018	CbGpPWpGaD
Danazol—Back pain—Methotrexate—bone cancer	0.000286	0.00328	CcSEcCtD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000285	0.00179	CbGpPWpGaD
Danazol—Chills—Epirubicin—bone cancer	0.000285	0.00327	CcSEcCtD
Danazol—Visual impairment—Doxorubicin—bone cancer	0.000283	0.00325	CcSEcCtD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000281	0.00176	CbGpPWpGaD
Danazol—Alopecia—Epirubicin—bone cancer	0.000281	0.00322	CcSEcCtD
Danazol—ESR1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.00028	0.00175	CbGpPWpGaD
Danazol—Vomiting—Cisplatin—bone cancer	0.000279	0.00321	CcSEcCtD
Danazol—Vision blurred—Methotrexate—bone cancer	0.000278	0.0032	CcSEcCtD
Danazol—Erythema multiforme—Doxorubicin—bone cancer	0.000278	0.00319	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000277	0.00174	CbGpPWpGaD
Danazol—Rash—Cisplatin—bone cancer	0.000277	0.00318	CcSEcCtD
Danazol—Dermatitis—Cisplatin—bone cancer	0.000277	0.00318	CcSEcCtD
Danazol—ESR1—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000273	0.00171	CbGpPWpGaD
Danazol—Flushing—Doxorubicin—bone cancer	0.000273	0.00313	CcSEcCtD
Danazol—AR—Androgen receptor signaling pathway—JUN—bone cancer	0.000273	0.00171	CbGpPWpGaD
Danazol—Tension—Epirubicin—bone cancer	0.000271	0.00312	CcSEcCtD
Danazol—Nervousness—Epirubicin—bone cancer	0.000269	0.00308	CcSEcCtD
Danazol—PGR—Signaling by ERBB4—MDM2—bone cancer	0.000268	0.00168	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—SMO—bone cancer	0.000268	0.00168	CbGpPWpGaD
Danazol—Back pain—Epirubicin—bone cancer	0.000267	0.00307	CcSEcCtD
Danazol—Muscle spasms—Epirubicin—bone cancer	0.000266	0.00305	CcSEcCtD
Danazol—Vertigo—Methotrexate—bone cancer	0.000265	0.00305	CcSEcCtD
Danazol—Leukopenia—Methotrexate—bone cancer	0.000265	0.00304	CcSEcCtD
Danazol—Chills—Doxorubicin—bone cancer	0.000264	0.00303	CcSEcCtD
Danazol—Nausea—Cisplatin—bone cancer	0.000261	0.003	CcSEcCtD
Danazol—Progesterone—CYP3A4—bone cancer	0.000261	0.0367	CrCbGaD
Danazol—Vision blurred—Epirubicin—bone cancer	0.000261	0.00299	CcSEcCtD
Danazol—ESR1—Regulation of Telomerase—JUN—bone cancer	0.00026	0.00163	CbGpPWpGaD
Danazol—Alopecia—Doxorubicin—bone cancer	0.00026	0.00298	CcSEcCtD
Danazol—CCL2—Signaling Pathways—GRM4—bone cancer	0.000259	0.00162	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—RGS1—bone cancer	0.000259	0.00162	CbGpPWpGaD
Danazol—Convulsion—Methotrexate—bone cancer	0.000256	0.00294	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—JUN—bone cancer	0.000254	0.00159	CbGpPWpGaD
Danazol—Arthralgia—Methotrexate—bone cancer	0.000252	0.00289	CcSEcCtD
Danazol—Tension—Doxorubicin—bone cancer	0.000251	0.00288	CcSEcCtD
Danazol—Nervousness—Doxorubicin—bone cancer	0.000249	0.00285	CcSEcCtD
Danazol—Vertigo—Epirubicin—bone cancer	0.000248	0.00285	CcSEcCtD
Danazol—ESR1—LKB1 signaling events—TP53—bone cancer	0.000248	0.00155	CbGpPWpGaD
Danazol—Syncope—Epirubicin—bone cancer	0.000248	0.00285	CcSEcCtD
Danazol—ESR1—AP-1 transcription factor network—MMP9—bone cancer	0.000248	0.00155	CbGpPWpGaD
Danazol—Leukopenia—Epirubicin—bone cancer	0.000248	0.00284	CcSEcCtD
Danazol—Back pain—Doxorubicin—bone cancer	0.000248	0.00284	CcSEcCtD
Danazol—Testosterone—CYP3A4—bone cancer	0.000247	0.0347	CrCbGaD
Danazol—GNRHR—GPCR downstream signaling—GNA11—bone cancer	0.000247	0.00154	CbGpPWpGaD
Danazol—Muscle spasms—Doxorubicin—bone cancer	0.000246	0.00283	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000245	0.00154	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—GNA11—bone cancer	0.000245	0.00153	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—SMO—bone cancer	0.000245	0.00153	CbGpPWpGaD
Danazol—Palpitations—Epirubicin—bone cancer	0.000244	0.00281	CcSEcCtD
Danazol—Loss of consciousness—Epirubicin—bone cancer	0.000243	0.00279	CcSEcCtD
Danazol—ESR1—Generic Transcription Pathway—NR1I2—bone cancer	0.000243	0.00152	CbGpPWpGaD
Danazol—Vision blurred—Doxorubicin—bone cancer	0.000241	0.00277	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000241	0.00151	CbGpPWpGaD
Danazol—Convulsion—Epirubicin—bone cancer	0.00024	0.00275	CcSEcCtD
Danazol—Hypertension—Epirubicin—bone cancer	0.000239	0.00274	CcSEcCtD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000239	0.00149	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000238	0.00149	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—GRM4—bone cancer	0.000237	0.00148	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—RGS1—bone cancer	0.000237	0.00148	CbGpPWpGaD
Danazol—Thrombocytopenia—Methotrexate—bone cancer	0.000236	0.00271	CcSEcCtD
Danazol—Arthralgia—Epirubicin—bone cancer	0.000235	0.0027	CcSEcCtD
Danazol—Anxiety—Epirubicin—bone cancer	0.000235	0.00269	CcSEcCtD
Danazol—Hyperhidrosis—Methotrexate—bone cancer	0.000233	0.00268	CcSEcCtD
Danazol—Vertigo—Doxorubicin—bone cancer	0.00023	0.00264	CcSEcCtD
Danazol—AR—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.00023	0.00144	CbGpPWpGaD
Danazol—Syncope—Doxorubicin—bone cancer	0.000229	0.00264	CcSEcCtD
Danazol—Leukopenia—Doxorubicin—bone cancer	0.000229	0.00263	CcSEcCtD
Danazol—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.000226	0.00142	CbGpPWpGaD
Danazol—Palpitations—Doxorubicin—bone cancer	0.000226	0.0026	CcSEcCtD
Danazol—Oedema—Epirubicin—bone cancer	0.000226	0.00259	CcSEcCtD
Danazol—Loss of consciousness—Doxorubicin—bone cancer	0.000225	0.00258	CcSEcCtD
Danazol—CCL2—Signaling Pathways—GRM1—bone cancer	0.000224	0.0014	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—GNA11—bone cancer	0.000224	0.0014	CbGpPWpGaD
Danazol—GNRHR—GPCR downstream signaling—IL3—bone cancer	0.000223	0.0014	CbGpPWpGaD
Danazol—Shock—Epirubicin—bone cancer	0.000222	0.00255	CcSEcCtD
Danazol—CCL2—Signaling by GPCR—IL3—bone cancer	0.000222	0.00139	CbGpPWpGaD
Danazol—Convulsion—Doxorubicin—bone cancer	0.000222	0.00255	CcSEcCtD
Danazol—Thrombocytopenia—Epirubicin—bone cancer	0.000221	0.00254	CcSEcCtD
Danazol—Hypertension—Doxorubicin—bone cancer	0.000221	0.00254	CcSEcCtD
Danazol—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.00022	0.00138	CbGpPWpGaD
Danazol—Tachycardia—Epirubicin—bone cancer	0.00022	0.00253	CcSEcCtD
Danazol—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00022	0.00252	CcSEcCtD
Danazol—AR—Gene Expression—FUS—bone cancer	0.000219	0.00137	CbGpPWpGaD
Danazol—Hyperhidrosis—Epirubicin—bone cancer	0.000218	0.00251	CcSEcCtD
Danazol—Arthralgia—Doxorubicin—bone cancer	0.000218	0.0025	CcSEcCtD
Danazol—Anxiety—Doxorubicin—bone cancer	0.000217	0.00249	CcSEcCtD
Danazol—Paraesthesia—Methotrexate—bone cancer	0.000217	0.00249	CcSEcCtD
Danazol—AR—Androgen receptor signaling pathway—EGFR—bone cancer	0.000214	0.00134	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000213	0.00134	CbGpPWpGaD
Danazol—Dyspepsia—Methotrexate—bone cancer	0.000212	0.00244	CcSEcCtD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000211	0.00132	CbGpPWpGaD
Danazol—Oedema—Doxorubicin—bone cancer	0.000209	0.0024	CcSEcCtD
Danazol—Fatigue—Methotrexate—bone cancer	0.000208	0.00239	CcSEcCtD
Danazol—CYP19A1—Metabolism—NDUFA12—bone cancer	0.000208	0.0013	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000207	0.0013	CbGpPWpGaD
Danazol—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000206	0.00236	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000205	0.00129	CbGpPWpGaD
Danazol—Shock—Doxorubicin—bone cancer	0.000205	0.00236	CcSEcCtD
Danazol—GNRHR—Signaling Pathways—GRM1—bone cancer	0.000205	0.00128	CbGpPWpGaD
Danazol—ESR1—Regulation of Telomerase—EGFR—bone cancer	0.000205	0.00128	CbGpPWpGaD
Danazol—Thrombocytopenia—Doxorubicin—bone cancer	0.000204	0.00235	CcSEcCtD
Danazol—Tachycardia—Doxorubicin—bone cancer	0.000204	0.00234	CcSEcCtD
Danazol—GNRHR—Signaling by GPCR—IL3—bone cancer	0.000203	0.00127	CbGpPWpGaD
Danazol—Paraesthesia—Epirubicin—bone cancer	0.000203	0.00233	CcSEcCtD
Danazol—Hyperhidrosis—Doxorubicin—bone cancer	0.000202	0.00232	CcSEcCtD
Danazol—ESR1—Signaling by ERBB4—KIT—bone cancer	0.0002	0.00125	CbGpPWpGaD
Danazol—PGR—Gene Expression—NR1I2—bone cancer	0.000199	0.00125	CbGpPWpGaD
Danazol—Dyspepsia—Epirubicin—bone cancer	0.000199	0.00228	CcSEcCtD
Danazol—Fatigue—Epirubicin—bone cancer	0.000195	0.00223	CcSEcCtD
Danazol—Constipation—Epirubicin—bone cancer	0.000193	0.00222	CcSEcCtD
Danazol—Urticaria—Methotrexate—bone cancer	0.000192	0.0022	CcSEcCtD
Danazol—Body temperature increased—Methotrexate—bone cancer	0.000191	0.00219	CcSEcCtD
Danazol—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.00019	0.00219	CcSEcCtD
Danazol—ESR1—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.000189	0.00118	CbGpPWpGaD
Danazol—Paraesthesia—Doxorubicin—bone cancer	0.000188	0.00215	CcSEcCtD
Danazol—ESR1—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000186	0.00116	CbGpPWpGaD
Danazol—Dyspepsia—Doxorubicin—bone cancer	0.000184	0.00211	CcSEcCtD
Danazol—PGR—Signaling by ERBB4—EGFR—bone cancer	0.000183	0.00115	CbGpPWpGaD
Danazol—Fatigue—Doxorubicin—bone cancer	0.00018	0.00207	CcSEcCtD
Danazol—Urticaria—Epirubicin—bone cancer	0.000179	0.00206	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000179	0.00112	CbGpPWpGaD
Danazol—Constipation—Doxorubicin—bone cancer	0.000179	0.00205	CcSEcCtD
Danazol—Body temperature increased—Epirubicin—bone cancer	0.000178	0.00205	CcSEcCtD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000177	0.00111	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000177	0.00111	CbGpPWpGaD
Danazol—AR—SIDS Susceptibility Pathways—JUN—bone cancer	0.000174	0.00109	CbGpPWpGaD
Danazol—Asthenia—Methotrexate—bone cancer	0.000173	0.00199	CcSEcCtD
Danazol—CYP19A1—Metabolism—NT5C3A—bone cancer	0.000172	0.00108	CbGpPWpGaD
Danazol—Pruritus—Methotrexate—bone cancer	0.000171	0.00196	CcSEcCtD
Danazol—AR—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.00017	0.00107	CbGpPWpGaD
Danazol—ESR1—Gene Expression—FUS—bone cancer	0.000169	0.00106	CbGpPWpGaD
Danazol—ESR1—AP-1 transcription factor network—TP53—bone cancer	0.000168	0.00105	CbGpPWpGaD
Danazol—Urticaria—Doxorubicin—bone cancer	0.000166	0.00191	CcSEcCtD
Danazol—Body temperature increased—Doxorubicin—bone cancer	0.000165	0.0019	CcSEcCtD
Danazol—AR—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000164	0.00103	CbGpPWpGaD
Danazol—Asthenia—Epirubicin—bone cancer	0.000162	0.00186	CcSEcCtD
Danazol—Pruritus—Epirubicin—bone cancer	0.00016	0.00183	CcSEcCtD
Danazol—Dizziness—Methotrexate—bone cancer	0.000159	0.00183	CcSEcCtD
Danazol—ESR1—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000158	0.000991	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—SMO—bone cancer	0.000158	0.00099	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—MDM2—bone cancer	0.000157	0.000986	CbGpPWpGaD
Danazol—CCL2—Metabolism of proteins—MMP2—bone cancer	0.000157	0.000985	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000154	0.000962	CbGpPWpGaD
Danazol—Vomiting—Methotrexate—bone cancer	0.000153	0.00176	CcSEcCtD
Danazol—Rash—Methotrexate—bone cancer	0.000152	0.00175	CcSEcCtD
Danazol—Dermatitis—Methotrexate—bone cancer	0.000152	0.00174	CcSEcCtD
Danazol—AR—Gene Expression—NR1I2—bone cancer	0.000152	0.000949	CbGpPWpGaD
Danazol—Headache—Methotrexate—bone cancer	0.000151	0.00174	CcSEcCtD
Danazol—Asthenia—Doxorubicin—bone cancer	0.00015	0.00172	CcSEcCtD
Danazol—PGR—Signaling Pathways—RGS1—bone cancer	0.000149	0.000934	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—GRM4—bone cancer	0.000149	0.000934	CbGpPWpGaD
Danazol—Dizziness—Epirubicin—bone cancer	0.000149	0.00171	CcSEcCtD
Danazol—AR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000148	0.000927	CbGpPWpGaD
Danazol—Pruritus—Doxorubicin—bone cancer	0.000148	0.0017	CcSEcCtD
Danazol—PGR—Gene Expression—EIF2S1—bone cancer	0.000147	0.00092	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—GNA11—bone cancer	0.000145	0.000905	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—SMO—bone cancer	0.000145	0.000905	CbGpPWpGaD
Danazol—Vomiting—Epirubicin—bone cancer	0.000143	0.00165	CcSEcCtD
Danazol—Nausea—Methotrexate—bone cancer	0.000143	0.00165	CcSEcCtD
Danazol—Rash—Epirubicin—bone cancer	0.000142	0.00163	CcSEcCtD
Danazol—Dermatitis—Epirubicin—bone cancer	0.000142	0.00163	CcSEcCtD
Danazol—Headache—Epirubicin—bone cancer	0.000141	0.00162	CcSEcCtD
Danazol—AR—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.00014	0.000879	CbGpPWpGaD
Danazol—Dizziness—Doxorubicin—bone cancer	0.000138	0.00159	CcSEcCtD
Danazol—ESR1—Integrated Breast Cancer Pathway—JUN—bone cancer	0.000138	0.000861	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—ATF1—bone cancer	0.000134	0.000842	CbGpPWpGaD
Danazol—Nausea—Epirubicin—bone cancer	0.000134	0.00154	CcSEcCtD
Danazol—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000134	0.000836	CbGpPWpGaD
Danazol—Vomiting—Doxorubicin—bone cancer	0.000133	0.00152	CcSEcCtD
Danazol—GNRHR—Signaling Pathways—GNA11—bone cancer	0.000132	0.000828	CbGpPWpGaD
Danazol—Rash—Doxorubicin—bone cancer	0.000132	0.00151	CcSEcCtD
Danazol—Dermatitis—Doxorubicin—bone cancer	0.000132	0.00151	CcSEcCtD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000131	0.000821	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IL3—bone cancer	0.000131	0.000821	CbGpPWpGaD
Danazol—Headache—Doxorubicin—bone cancer	0.000131	0.0015	CcSEcCtD
Danazol—PGR—Signaling Pathways—GRM1—bone cancer	0.000129	0.00081	CbGpPWpGaD
Danazol—PGR—Gene Expression—EZH2—bone cancer	0.000128	0.000799	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000126	0.000792	CbGpPWpGaD
Danazol—Nausea—Doxorubicin—bone cancer	0.000124	0.00142	CcSEcCtD
Danazol—GNRHR—Signaling Pathways—ATF1—bone cancer	0.000123	0.00077	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000121	0.000756	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IL3—bone cancer	0.00012	0.000751	CbGpPWpGaD
Danazol—AR—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000118	0.000738	CbGpPWpGaD
Danazol—ESR1—Gene Expression—NR1I2—bone cancer	0.000117	0.000731	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000116	0.000728	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000114	0.000714	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TGFBR2—bone cancer	0.000112	0.000702	CbGpPWpGaD
Danazol—AR—Gene Expression—EIF2S1—bone cancer	0.000112	0.000701	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—EGFR—bone cancer	0.000108	0.000677	CbGpPWpGaD
Danazol—ESR1—Signaling by ERBB4—EGFR—bone cancer	0.000108	0.000674	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—IGF1R—bone cancer	0.000105	0.00066	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TGFBR2—bone cancer	0.000103	0.000642	CbGpPWpGaD
Danazol—CYP19A1—Integrated Breast Cancer Pathway—TP53—bone cancer	0.000101	0.000635	CbGpPWpGaD
Danazol—AR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	9.77e-05	0.000612	CbGpPWpGaD
Danazol—AR—Gene Expression—EZH2—bone cancer	9.73e-05	0.000609	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—IGF1R—bone cancer	9.65e-05	0.000604	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—SMO—bone cancer	9.12e-05	0.000571	CbGpPWpGaD
Danazol—ESR1—Integrated Breast Cancer Pathway—TP53—bone cancer	9.08e-05	0.000569	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	8.96e-05	0.000561	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—GRM4—bone cancer	8.76e-05	0.000548	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—RGS1—bone cancer	8.76e-05	0.000548	CbGpPWpGaD
Danazol—CYP3A4—Biological oxidations—GSTP1—bone cancer	8.65e-05	0.000542	CbGpPWpGaD
Danazol—ESR1—Gene Expression—EIF2S1—bone cancer	8.63e-05	0.00054	CbGpPWpGaD
Danazol—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	8.53e-05	0.000534	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—GNA11—bone cancer	8.34e-05	0.000522	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—ATF1—bone cancer	7.75e-05	0.000485	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—KIT—bone cancer	7.65e-05	0.000479	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—GRM1—bone cancer	7.59e-05	0.000476	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IL3—bone cancer	7.56e-05	0.000473	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—ENO2—bone cancer	7.54e-05	0.000472	CbGpPWpGaD
Danazol—ESR1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	7.52e-05	0.000471	CbGpPWpGaD
Danazol—ESR1—Gene Expression—EZH2—bone cancer	7.49e-05	0.000469	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—BRAF—bone cancer	7.19e-05	0.00045	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—KIT—bone cancer	7e-05	0.000438	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—DHFR—bone cancer	7e-05	0.000438	CbGpPWpGaD
Danazol—CCL2—Signaling by GPCR—EGFR—bone cancer	6.97e-05	0.000436	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—BRAF—bone cancer	6.58e-05	0.000412	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—GNA11—bone cancer	6.54e-05	0.000409	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TGFBR2—bone cancer	6.47e-05	0.000405	CbGpPWpGaD
Danazol—GNRHR—Signaling by GPCR—EGFR—bone cancer	6.37e-05	0.000399	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—IGF1R—bone cancer	6.08e-05	0.000381	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—NDUFA12—bone cancer	6.06e-05	0.00038	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—MDM2—bone cancer	6.02e-05	0.000377	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—CYP3A4—bone cancer	5.93e-05	0.000371	CbGpPWpGaD
Danazol—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	5.9e-05	0.000369	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MDM2—bone cancer	5.51e-05	0.000345	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—SMO—bone cancer	5.35e-05	0.000335	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—JUN—bone cancer	5.24e-05	0.000328	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—MMP9—bone cancer	5.09e-05	0.000319	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—GSTP1—bone cancer	5.07e-05	0.000317	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—NT5C3A—bone cancer	5.02e-05	0.000315	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—GNA11—bone cancer	4.89e-05	0.000306	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—JUN—bone cancer	4.79e-05	0.0003	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—MMP9—bone cancer	4.66e-05	0.000292	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—ATF1—bone cancer	4.55e-05	0.000285	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IL3—bone cancer	4.44e-05	0.000278	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—KIT—bone cancer	4.41e-05	0.000276	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—BRAF—bone cancer	4.15e-05	0.00026	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—EGFR—bone cancer	4.12e-05	0.000258	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TGFBR2—bone cancer	3.79e-05	0.000238	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—EGFR—bone cancer	3.77e-05	0.000236	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—IGF1R—bone cancer	3.57e-05	0.000224	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MDM2—bone cancer	3.47e-05	0.000218	CbGpPWpGaD
Danazol—CCL2—Signaling Pathways—TP53—bone cancer	3.46e-05	0.000216	CbGpPWpGaD
Danazol—GNRHR—Signaling Pathways—TP53—bone cancer	3.16e-05	0.000198	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—JUN—bone cancer	3.02e-05	0.000189	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—MMP9—bone cancer	2.94e-05	0.000184	CbGpPWpGaD
Danazol—CYP19A1—Metabolism—PTGS2—bone cancer	2.63e-05	0.000164	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—KIT—bone cancer	2.59e-05	0.000162	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—BRAF—bone cancer	2.43e-05	0.000152	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—EGFR—bone cancer	2.37e-05	0.000149	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—ENO2—bone cancer	2.2e-05	0.000138	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—DHFR—bone cancer	2.04e-05	0.000128	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MDM2—bone cancer	2.04e-05	0.000128	CbGpPWpGaD
Danazol—PGR—Signaling Pathways—TP53—bone cancer	1.99e-05	0.000125	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—GNA11—bone cancer	1.91e-05	0.000119	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—JUN—bone cancer	1.77e-05	0.000111	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—MMP9—bone cancer	1.72e-05	0.000108	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—GSTP1—bone cancer	1.48e-05	9.26e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—EGFR—bone cancer	1.39e-05	8.73e-05	CbGpPWpGaD
Danazol—ESR1—Signaling Pathways—TP53—bone cancer	1.17e-05	7.33e-05	CbGpPWpGaD
Danazol—CYP3A4—Metabolism—PTGS2—bone cancer	7.66e-06	4.8e-05	CbGpPWpGaD
